No Data
Deere & Co, RepliCel, and others [Emerging Markets Press Release]
Following the company split (simplified establishment split) at <155A>, a subsidiary was established. At <3935>, deere & co requested a market change to the Tokyo Stock Exchange's standard market. At <4978>, Cell AMED received approval for the market change. The grant amount for the 2023 fiscal year for the Public Offering Business 'Basic Technology Development Project for Industrialization of Regenerative Medicine and Gene Therapy' has been determined.
Ishin, JSH, Hatchwork, Solacom, Dai, Sinka, Cauris, information global strategy technology
■ ISIN <143A> Estimated number of shares to be released: 1,344,700 shares (estimated) Release date: 09/21/2024 Target shareholders: Estimated Shares: Tomoyoshi Akashi - 432,200 shares Michio Matsuura - 19,200 shares (Shares) Bright Stone - 760,000 shares Kazutaka Muraguchi - 53,300 shares Satoshi Kitaoka - 32,000 shares Hideaki Yoshida - 16,000 shares Hirohiro Maruyama - 16,000 shares Dai Matsumoto
OncoLis Bio, Modaris, and others.
<4588> OncoReBio's 20th subscription rights (with exercise price adjustment clause and exercise suspension clause) issued 0.46 million shares of exercised stocks since the beginning of the month. <4883> Modaris' 12th subscription rights (with exercise price adjustment clause) completed the exercise and issued 2.227 million shares of exercised stocks since the beginning of the month. <9338> INFORIZCH established overseas subsidiaries in the United Kingdom. <9553> MicroAd transferred stocks with changes to its consolidated subsidiary (MADS). <4424> Amaizia with My Medical
Information Strategy and Technology: Interim Report - 16th Period (January 1, 2024 - December 31, 2024)
Information Strategy and Technology: Financial Results Summary for the Second Quarter (Interim Period) of December 2024.
Information Strategy and Technology: FY December 2024 Q2 (interim period) financial results announcement [Japan GAAP] (non-consolidated)
No Data
No Data